Advertisement

Topics

Associations, Outcomes and Genomics of GB Virus C, Hepatitis C Virus and Human Immunodeficiency Virus Infection

2014-08-27 03:51:07 | BioPortfolio

Summary

The purpose of this study is to examine the effect of GB virus C (GBV-C) on the natural history of chronic hepatitis C virus (HCV) infection in subjects co-infected with HIV and HCV. The other aspect of the study is to assess the effect of GBV-C on the severity of liver disease due to chronic hepatitis C in subjects co-infected with HIV and HCV. This will be done by determining the point prevalence of co-infection retrospectively then following that cohort prospectively. In addition, further individuals will be recruited in a prospective manner.

Description

Background and Research Plan:

GBV-C and hepatitis G virus (HGV) are both RNA viruses from the Flaviviridae family. Molecular characterization of these viruses has shown them to be virtually identical to each other (1,2). GBV-C was first isolated in 1995 from an archival blood sample obtained in the 1960s from a surgeon with acute non A-E hepatitis (3). GBV-C has a 29% amino acid sequence homology with Hepatitis C Virus (HCV), another flavivirus (4). However, GBV-C in contrast to HCV, is not hepatotropic as the virus neither replicates primarily in hepatocytes nor causes acute or chronic hepatitis. Indeed, GBV-C does not cause any specific disease nor does it represent a substantial health risk in humans. Nevertheless, GBV-C infection is relatively common with a 2% prevalence rate in healthy blood donors, the majority of whom clear the virus and develop antibodies to the envelope glycoprotein E2.

HIV infection has a particularly high rate of co-infection with GBV-C. Studies suggest that co-infection leads to a beneficial effect on the course of HIV (5,6,7) with co-infection associated with a significantly lower mortality rate among HIV-infected subjects compared to those not infected with GBV-C. The mechanism of the beneficial effect of GBV-C on the course of HIV infection is obscure.

Among new cases of non-A, non-B hepatitis in the United States, 18 percent are positive for GBV-C, and 80% of these patients are also infected with HCV. Amongst patients with HCV, 10-20% have GBV-C RNA in their serum (4). In another report 189 patients with chronic HCV infection were evaluated; 21 (11%) were positive for GBV-C RNA (8). The course of the HCV infection and the response to interferon-alfa were not affected by co-infection with GBV-C. Interferon-alfa led to a decrease in GBV-C RNA titers that was not sustained after the cessation of therapy. Similar findings were noted in another study in which liver biopsies were performed (9). Detailed histopathologic examination revealed no difference between the patients infected with HCV alone and the 15 percent who were co-infected with GBV-C. There have been no studies to date looking at the effect GBV-C, HCV and HIV have on each other.

Our previous studies into HIV and GBV-C have suggested that co-infection is common. Active GBV-C infection is frequently observed in persons involved in high-risk sexual activity and with HIV infection. Homosexual intercourse appears to be a more effective means of transmission of GBV-C. GBV-C has the same epidemiology and transmission as HIV and underlines the intimate association between GBV-C and HIV (10).

Methods/Experimental Design:

Stored sera is available from people who have attended the Hepatitis and HIV clinics at the Alfred Hospital. Sera is available back to approximately 1990 and has been stored at minus 20ºC and as such is suitable for GBV-C detection particularly RNA by PCR. Of the sera stored by the HIV clinic 203 patients are known to be co-infected with HCV who are currently still alive. Once ethics committee approval is obtained we propose to contact these groups of people and see if they would participate in this study. Once consent is obtained we plan to perform the following.

A. Stored sera will be retrospectively examined for the point prevalence of infection with HCV, GBV-C and HIV. These individuals will then be followed up in a prospective manner assessing the progression of liver disease and other factors as outlined in Tables 1 to 4.

B. New subjects attending the Alfred Hospital Hepatitis or HIV clinics will be recruited and followed prospectively also as outlined in Tables 1 to 4.

C. An age and sex matched control group infected with HCV alone will be identified via the Alfred Hospital Hepatitis clinic. This clinic has a large cohort of well-characterized HCV infected subjects that extends back to 1989.

The inclusion and exclusion criteria for the study are as follows:

Inclusion criteria

1. Sera available and appropriate for testing. Including serial sera over a period of time. (retrospective analysis)

2. HIV serology positive.

3. Unequivocal HCV antibody positive or HCV RNA positive.

Exclusion criteria

1. Those without sera available.

2. Those unwilling to give informed consent.

3. Persons with Hepatitis B Virus infection, as defined by the presence of Hepatitis B surface antigen and/or Hepatitis B Virus DNA positive.

Where possible information will also be obtained about these people by interview, examining the medical records or discussion with their General Practitioners. Subjects will also be encouraged to attend the hospital in person where a clinical exam can be performed. If insufficient sera is stored further blood will be drawn at this time and examined for HCV, HIV and GBV-C related parameters as outlined in the tables below. A study specific questionnaire will be generated in which subjects will be asked to complete a confidential questionnaire that contains information related to demographic and behavioral factors that may contribute to the acquisition of GBV-C, HCV or HIV infection or various combinations of the above. Demographic variables will include age, sex, country of birth, and occupation. Information relevant to HIV infection including the use of HAART and the presence or absence of AIDS defining syndromes will be obtained. The questionnaire will attempt to identify the approximate time of acquisition of both HCV and HIV. In addition, the extent of liver disease will be assessed, alcohol consumption will be quantified and information will be gathered on previous treatment with Interferon and Ribavirin.

The main outcomes of this study will be liver related morbidity, such as chronic hepatitis, cirrhosis or hepatocellular cancer and overall patient survival. The detailed information contained in the following tables will be obtained from interview, medical records and clinical examination:

Table 1: GBV-C

1. Testing sera for GBV-C RNA and E2 antibodies to GBV-C.

2. Performing testing at one-year intervals if sera is available.

Table 2: HIV

1. CD4 count (buffy coat) in HIV positive.

2. HIV viral load.

3. Use of highly active antiretroviral therapy (HAART) and other retroviral treatment and/or change in treatment.

4. Complications of HIV/AIDS and AIDS defining illnesses.

Table 3: Liver disease (HCV)

1. HCV viral load and genotype.

2. Child-Pugh classification based on levels of bilirubin, albumin and clotting profiles, and the presence of ascites and encephalopathy.

3. Complications of liver disease: ascites, encephalopathy, variceal bleeding and hepatocellular carcinoma.

4. ALT and AST levels as well as AST/ALT ratio.

5. Alpha Feto Protein (AFP) level.

6. Liver histology at biopsy with assessment of inflammation grade, stage of fibrosis and severity of hepatic steatosis.

7. Liver ultrasound results.

8. Results of endoscopy, i.e. features of portal hypertension

Table 4: Survival Data

1. Has patient died?

2. Date of death.

3. Cause of death.

Results will be statistically examined by univariate and multivariate analysis in terms of clinical outcomes with respect to chronic hepatitis C liver disease between GBV-C positive and negative groups in the HIV co-infected cohort compared with the HCV infected cohort alone. See following Table 5.

Table 5: Study Design

Study Group No.1 HCV +ve, HIV +ve, GBV-C RNA+ve. Study Group No.2 HCV +ve, HIV +ve, GBV-C RNA-ve. Control Group HCV +ve alone.

References relevant to this project (from literature search)

1. Linnen J, Wages J, Zhang-Keck Z, et al. Molecular cloning and disease association of hepatitis G virus: A new transfusion transmissible agent. Science 1996; 271:505-8.

2. Alter HJ. The cloning and clinical implications of HGV and HGBV-C. N Engl J Med 1996; 334:1536-7.

3. Simons JN, Leary TP, Dawson GJ, et al. Isolation of novel virus-like sequences associated with Human hepatitis. Nat Med 1995;1:564-9.

4. Di Bisceglie AM. Hepatitis G virus infection: A work in progress. Ann Intern Med 1996; 125:772.

5. Tillman HL, Heiken H, Knapik-Botor A, et al. Infection with GB virus C and reduced mortality among HIV-infected patients. N Engl J Med 2001; 345:715-24.

6. Xiang J, Wunschmann S, Diekema DJ, et al. Effect of coinfection with GB virus C on survival among patients with HIV infection. N Engl J Med 2001;345:707-14.

7. Lefrere JJ, Roudot-Thoraval F, Morand-Joubert L, et al. Carriage of GB virus C/hepatitis G virus RNA is associated with a slower immunologic, virologic and clinical progression of human Immunodeficiency virus disease in coinfected persons. J Infect Dis 1999; 179:783-9.

8. Tanaka E, Alter HJ, Nakatsuji Y, et al. Effect of hepatitis G virus infection on chronic hepatitis C. Ann Intern Med 1996;125:740-3.

9. Bralet MP, Roudot-Thoraval F, Pawlotsky JM, et al. Histopathologic impact of GB virus C infection on chronic hepatitis C. Gastroenterology 1997;112:188-92.

10. Berzsenyi MD, Bowden SD, Bailey MJ, et al. Sexual and blood-borne transmission of GB virus C and its association with Human Immunodeficiency Virus. In press.

Study Design

Observational Model: Defined Population, Observational Model: Natural History, Time Perspective: Longitudinal, Time Perspective: Retrospective

Conditions

Hepatitis C

Location

Alfred Hospital
Melbourne
Victoria
Australia
3181

Status

Recruiting

Source

Bayside Health

Results (where available)

View Results

Links

Published on BioPortfolio: 2014-08-27T03:51:07-0400

Clinical Trials [1264 Associated Clinical Trials listed on BioPortfolio]

Efficacy Study of Combined Hepatitis A and Hepatitis B Vaccine to Protect Against Hepatitis B in Hemodialysis Patients

Does vaccinating hemodialysis patients with Twinrix® (combination vaccine against hepatitis A and hepatitis B) result in a difference in hepatitis B antibody response in comparison to the...

Investigation of Hepatitis B and Hepatitis C in Taiwan

The purpose of this study is to investigate the differences of genotypes of hepatitis B and hepatitis C in Taiwan.

Management of Hepatitis C in HIV-Infected and Uninfected IDUs

The purpose of this study is to determine if hepatitis C has damaged the liver, whether each subject's hepatitis C is treatable with currently available medicines, whether patient educatio...

Activation of Hepatitis B Virus (HBV) in Hepatitis B Surface Antigen (HBsAg) - Negative But Hepatitis B Core Antibody (Anti-HBc) - Positive Patients

Individuals with resolved hepatitis B, characterized as hepatitis B surface antigen (HBsAg)-negative and hepatitis B core antibody-positive, have latent hepatitis B virus (HBV) infection i...

A Safety and Efficacy Study of the Hepatitis E Vaccine in Nepal.

The purpose of this study is to determine if a hepatitis E vaccine is safe and able to prevent symptomatic liver disease due to the hepatitis E virus.

PubMed Articles [1283 Associated PubMed Articles listed on BioPortfolio]

Prevalence and incidence of hepatitis delta in patients with chronic hepatitis B in Spain.

Hepatitis delta virus (HDV) is a defective agent that only replicates in the presence of the hepatitis B virus. Accordingly, HDV acquisition may occur as superinfection of HBsAg+ carriers or following...

Prevalence of non A to E hepatitis in Mumbai, India.

Acute viral hepatitis is a common problem in India. World wide data shows that 5 to 20 percent of this is caused by non A-E hepatitis. There is no data in India regarding non A-E hepatitis. We carried...

Clinical and laboratory characteristics of hepatitis d in Republic of Sakha (Yakutia).

Inrtroduction: The epidemiological situation for hepatitis D has changed significantly. Reduced population authors infection due to a sharp decline in hospitalizations from Central Asia regions, the C...

Hepatitis B And Hepatitis C Virus In Women With First Pregnancy.

Hepatitis B and Hepatitis C are amongst the leading causes of morbidity and mortality in pregnant women throughout the globe. This study is aimed at determining the frequency of these infections among...

Quantitative Hepatitis B e Antigen: A Better Predictor of Hepatitis B Virus DNA than Quantitative Hepatitis B Surface Antigen.

Hepatitis B surface antigen is usually secreted by infected hepatocytes in the form of subviral particles rather than infectious virions, while the hepatitis B e antigen originates from the core gene ...

Medical and Biotech [MESH] Definitions

INFLAMMATION of the LIVER in humans due to infection by VIRUSES. There are several significant types of human viral hepatitis with infection caused by enteric-transmission (HEPATITIS A; HEPATITIS E) or blood transfusion (HEPATITIS B; HEPATITIS C; and HEPATITIS D).

A family of hepatotropic DNA viruses which contains double-stranded DNA genomes and causes hepatitis in humans and animals. There are two genera: AVIHEPADNAVIRUS and ORTHOHEPADNAVIRUS. Hepadnaviruses include HEPATITIS B VIRUS, duck hepatitis B virus (HEPATITIS B VIRUS, DUCK), heron hepatitis B virus, ground squirrel hepatitis virus, and woodchuck hepatitis B virus (HEPATITIS B VIRUS, WOODCHUCK).

A species in the genus HEPATOVIRUS containing one serotype and two strains: HUMAN HEPATITIS A VIRUS and Simian hepatitis A virus causing hepatitis in humans (HEPATITIS A) and primates, respectively.

INFLAMMATION of the LIVER in humans caused by HEPATITIS DELTA VIRUS, a defective RNA virus that can only infect HEPATITIS B patients. For its viral coating, hepatitis delta virus requires the HEPATITIS B SURFACE ANTIGENS produced by these patients. Hepatitis D can occur either concomitantly with (coinfection) or subsequent to (superinfection) hepatitis B infection. Similar to hepatitis B, it is primarily transmitted by parenteral exposure, such as transfusion of contaminated blood or blood products, but can also be transmitted via sexual or intimate personal contact.

INFLAMMATION of the LIVER in humans caused by HEPATITIS C VIRUS, a single-stranded RNA virus. Its incubation period is 30-90 days. Hepatitis C is transmitted primarily by contaminated blood parenterally, and is often associated with transfusion and intravenous drug abuse. However, in a significant number of cases, the source of hepatitis C infection is unknown.

More From BioPortfolio on "Associations, Outcomes and Genomics of GB Virus C, Hepatitis C Virus and Human Immunodeficiency Virus Infection"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Gastroenterology
Astroesophageal Reflux Disease (GERD) Barrett's Esophagus Celiac Disease Cholesterol Crohn's Disease Gastroenterology Hepatitis Hepatology Irritable Bowel Syndrome (IBS) Pancreatitis Peptic Ulcer Disease...

Infectious-diseases
Antiretroviral Therapy Clostridium Difficile Ebola HIV & AIDS Infectious Diseases Influenza Malaria Measles Sepsis Swine Flu Tropical Medicine Tuberculosis Infectious diseases are caused by pathogenic...


Searches Linking to this Trial